Careers  |  Sign In  |  Register

Trial for Ebola Vaccine Gets Put On Hold

Reuters reports that an Ebola vaccine trial has been put on hiatus after four patients alleged that they were experiencing joint pains. The vaccine, developed by Merck and NewLink has been tested on fifty nine volunteers to date. Trials on the GlaxoSmithKline Ebola vaccine yielded no serious side effects in study subjects, and saw an immune response in all 20 volunteers who received the vaccine. The Merck-NewLink trial is expected to resume on up to 15 subjects in early January.

Read the article published by Reuters.